X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.04
    +0.00 (+0.00%)

    Market Cap: $400.55M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(16/35)
    Avg Surprise
    -9.63%
    Streak
    6 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.22 - $-0.16
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.21-11.1%
    60d ago$-0.20-6.2%
    30d ago$-0.20-6.2%
    7d ago$-0.19-3.2%
    Current$-0.19
    Revenue Consensus
    $2M
    Range$2M - $3M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.22 - $-0.02
    5 analysts
    Revenue Consensus
    $8M
    Range$7M - $9M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.19---
    Jun 26
    		$-0.13$-0.19+31.58%Beat+96.3%
    Mar 26
    		$-0.16$-0.20+20.00%Beat-500.0%
    Dec 25
    		$-0.22$-0.35+36.69%Beat-10.0%
    Sep 25
    		$-0.69$-0.79+12.66%Beat+87.2%
    Jun 25
    		$-3.47$-4.34+20.05%Beat-63.7%
    Mar 25
    		$0.04N/A+101.07%Beat+115.4%
    Dec 24
    		$-0.20$-0.16-26.98%Miss+93.3%
    Sep 24
    		$-5.40$-5.16-4.65%Miss-1700.0%
    Jun 24
    		$-2.12$0.75-382.67%Miss+78.6%
    Mar 24
    		$-0.26$-0.16-62.50%Miss-62.5%
    Dec 23
    		$-3.00$-4.55+34.07%Beat+65.5%
    Sep 23
    		$-0.30N/A+93.01%Beat+96.2%
    Jun 23
    		$-9.90$-4.93-100.81%Miss+45.0%
    Mar 23
    		$-0.16$-0.22+27.27%Beat+99.3%
    Dec 22
    		$-8.70$-7.24-20.17%Miss-866.7%
    Sep 22
    		$-7.80$-9.53+18.15%Beat+65.8%
    Jun 22
    		$-18.00$-19.25+6.49%Beat+18.9%
    Mar 22
    		$-21.60$-18.53-16.57%Miss+44.6%
    Dec 21
    		$-0.90$-0.68-32.35%Miss+1.1%
    Sep 21
    		$-22.80$-21.30-7.04%Miss+12.6%
    Jun 21
    		$-22.20$-22.08-0.54%Miss+2.6%
    Mar 21
    		$-39.00$-25.76-51.40%Miss-6864.3%
    Dec 20
    		$-0.91$-0.90-1.11%Miss+95.4%
    Sep 20
    		$-26.10$-21.97-18.80%Miss+28.7%
    Jun 20
    		$-22.80$-21.54-5.85%Miss+25.5%
    Mar 20
    		$-0.56$-0.80+30.00%Beat+99.7%
    Dec 19
    		$-19.80$-25.65+22.81%Beat-405.1%
    Sep 19
    		$-36.60$-32.00-14.38%Miss-702.6%
    Jun 19
    		$-30.60$-29.10-5.15%Miss-500.0%
    Mar 19
    		$-200.10$-98.97-102.18%Miss-4406.8%
    Dec 18
    		$-3.92$-4.44+11.71%Beat+61.1%
    Sep 18
    		$-4.56$-3.88-17.53%Miss+81.3%
    Jun 18
    		$-5.10$-4.90-4.08%Miss-862.3%
    Mar 18
    		$-4.44$-6.24+28.85%Beat-788.0%
    Dec 17
    		$-10.08$-17.80+43.37%Beat-
    Sep 17
    		$-24.36N/AN/ABeat-
    Jun 17
    		$-0.53$0.00N/AMiss-
    Mar 17
    		$-0.50$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.37EV/EBITDA1.10x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-186.10%
    ROE-113.10%ROIC-38.05%
    Financial Health
    Debt/Equity0.49xInterest Coverage-10.11x
    Current Ratio11.30xQuick Ratio11.02x
    Trading Statistics
    Beta0.39Avg Volume684.54K
    52-Week High$4.8352-Week Low$2.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.11
    SMA 20$4.20
    SMA 50$4.08
    SMA 200$3.93
    EMA 10$4.12
    EMA 20$4.13
    EMA 50$4.10
    EMA 200$4.12

    MACD

    Line: 0.00Signal: 0.03Hist: -0.02

    ADX

    ADX: 23.2+DI: 22.6-DI: 16.3

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down4.0
    PSAR$4.50

    Bollinger Bands

    Upper Band$4.48
    Lower Band$3.92
    %B Position1336%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    46.5

    Momentum Oscillators

    Stoch %K24.9
    Stoch %D28.0
    Williams %R-83.6
    ROC (10d)-6.0%
    Momentum-0.26
    CCI (20d)-111.5
    MFI (14d)41.9

    Volatility Measures

    ATR (14d)$0.23(5.6%)
    StdDev (20d)0.14
    Hist Vol61.4%(High)

    Volume Flow

    VWAP$4.05
    OBV217.4M
    AD Line39.6B
    CMF (20d)-0.073

    Volume Metrics

    Avg Vol (20d)700.6K
    Vol Ratio0.4x(Low)
    VWMA (20d)$4.25

    Pivot Points

    R3$4.41
    R2$4.32
    R1$4.18
    Pivot Point$4.09
    S1$3.95
    S2$3.86
    S3$3.72

    Advanced Oscillators

    TSI0.79
    Ultimate Osc45.2
    KST23.12

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.81M$2.71M$2.14M$1.96M$1.97M$28.81M$1.43M$560,000$563,000$0$3.06M$0
    Cost of Revenue$1.62M$598,000$364,000$351,000$326,000$4.72M$302,000$227,000$268,000$0$62,000$0
    Gross Profit$7.19M$2.11M$1.78M$1.61M$1.65M$24.09M$1.13M$333,000$295,000$0$-62,000$0
    Operating Expenses$23.58M$22.42M$25.90M$28.92M$27.88M$33.53M$36.85M$34.83M$-70,808,000$37.29M$25.20M$27.21M
    R&D$15.08M$15.45M$18.52M$17.34M$18.35M$18.51M$21.70M$19.17M$20.91M$19.85M$15.27M$19.08M
    SG&A$8.50M$6.97M$7.38M$11.59M$9.53M$15.02M$15.14M$15.66M$13.28M$17.43M$9.93M$8.13M
    Operating Income$-16,391,000$-20,306,000$-23,699,000$-27,509,000$-26,232,000$-9,443,000$-35,715,000$-34,500,000$71.10M$-37,289,000$-25,199,000$-27,214,000
    Interest Income$1.98M$2.10M$1.99M$901,000$665,000$1.02M$1.27M$1.87M$1.56M$1.07M$1.45M$1.39M
    Interest Expense$2.16M$2.13M$2.19M$2.26M$2.23M$2.20M$2.30M$2.41M$2.18M$1.87M$1.89M$1.63M
    Income Before Tax$-16,155,000$-20,241,000$-23,925,000$-29,845,000$-25,704,000$316,000$-39,563,000$-36,681,000$90.85M$-51,747,000$-19,097,000$-2,279,000
    Income Tax Expense$2,000$0$0$-30,000$37,000$34,000$258,000$15,000$18,000$19,000$33,000$26,000
    Net Income$-16,157,000$-20,241,000$-23,925,000$-29,815,000$-25,741,000$282,000$-39,821,000$-36,696,000$90.83M$-51,766,000$-19,130,000$-2,305,000
    EBITDA$-14,973,000$-19,989,000$-23,501,000$-28,266,000$-23,782,000$1.97M$-38,253,000$-35,871,000$91.66M$-50,877,000$-18,594,000$-1,929,000
    EBIT$-15,970,000$-20,212,000$-23,724,000$-28,489,000$-24,137,000$1.49M$-38,526,000$-36,138,000$91.46M$-50,939,000$-18,656,000$-2,033,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XFOR

    News

    X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts

    X4 Pharmaceuticals (NASDAQ:XFOR) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month target price of $11.25, significantly higher than its current share price of $4.21. The company recently reported better-than-expected quarterly EPS of -$0.13 and revenue of $8.81 million, though it remains unprofitable. Insider sales of 80,555 shares worth approximately $356,126 have occurred over the last three months, while institutional investors hold 72.03% of the stock.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

    Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including common stock and exercisable warrants. The ownership percentage is based on 99,146,743 shares of common stock outstanding as of July 31, 2026.

    Stock Titan•8/14/26•
    Neutral

    Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants

    Deep Track Capital and its affiliates have reported a beneficial ownership of 8.33% in X4 Pharmaceuticals (XFOR), totaling 8,040,894 shares with shared voting and dispositive power. This stake includes 2,162,137 Pre-Funded Warrants, which are subject to a 9.99% "Maximum Percentage" ownership cap, limiting their exercise if it would exceed this threshold. The ownership percentage is based on 96,481,833 shares, incorporating outstanding shares as of May 1, 2026, and warrant-issuable shares within the cap.

    Stock Titan•8/14/26•
    Neutral

    X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026)

    This article reports on an SEC Form 144 filing by X4 Pharmaceuticals, Inc. (XFOR) on August 13, 2026. The filing indicates a proposed sale of 24,576 shares of common stock with an aggregate market value of $111,943.68, acquired through restricted stock unit vesting. The filing also notes the company's recent news and other SEC filings.

    Stock Titan•8/14/26•
    Neutral

    X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award

    John Volpone, President of X4 Pharmaceuticals (NASDAQ: XFOR), sold 24,576 shares of company stock on August 12, 2026. This transaction was executed to cover personal income tax liabilities associated with the settlement of a restricted stock unit (RSU) award. Following the sale, Volpone beneficially owns 265,305 shares, including 193,254 restricted stock units.

    Kalkine Media•8/13/26•
    Neutral

    Frequently Asked Questions About XFOR

    Does XFOR pay dividends?
    X4 Pharmaceuticals Inc (XFOR) does not currently pay a regular dividend.
    What is XFOR's market cap?
    X4 Pharmaceuticals Inc (XFOR) has a market capitalization of $400.55M with a current stock price of $4.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In